Showing results (11-20 of 1,215) with videos related to
Sort By:
Pageof 122
Immunology|December 8, 2016
Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosisStephanie von Kutzleben, Gareth Pryce, Gavin Giovannoni, et al.The Lancet. Neurology|July 10, 2003
The therapeutic potential of cannabisDavid Baker, Gareth Pryce, Gavin Giovannoni, et al.Plos One|June 30, 2016
Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA SequencingIoanna Sevastou, Gareth Pryce, David Baker, et al.Trends in Pharmacological Sciences|December 2, 2005
In silico patent searching reveals a new cannabinoid receptorDavid Baker, Gareth Pryce, Wayne L Davies, et al.Ebiomedicine|February 6, 2017
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple SclerosisDavid Baker, Monica Marta, Gareth Pryce, et al.Journal of the Neurological Sciences|May 17, 2005
Cannabinoids and neuroprotection in CNS inflammatory diseaseSamuel J Jackson, Lara T Diemel, Gareth Pryce, et al.Brain : a Journal of Neurology|September 14, 2018
Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosisDavid Baker, Gareth Pryce, Sandra Amor, et al.Multiple Sclerosis and Related Disorders|April 17, 2015
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosisDavid Baker, Gareth Pryce, Samuel J Jackson, et al.Multiple Sclerosis and Related Disorders|June 17, 2017
Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitisEseberuo Sefia, Gareth Pryce, Ute-Christiane Meier, et al.Multiple Sclerosis and Related Disorders|July 10, 2020
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosisDavid Baker, Gareth Pryce, Louisa K James, et al.Pageof 122